Retatrutide, also known as LY3437943, is an investigational synthetic peptide with triple agonism of glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). Retatrutide activates GIP, GLP-1, and glucagon receptors, producing an integrated pharmacological signal that influences appetite, glucose metabolism and energy balance. According to the research conducted by Jastreboff et al., in a randomized, phase II obesity trial, the administration of Retatrutide resulted in substantial weight loss over a 48-week period, in a dose-dependent manner.
Retatrutide 30 mg refers to the quantity of retatrutide contained in a particular research preparation. The 30 mg quantity itself does not establish a pharmacological effect or correspond to a clinically validated dose. Published clinical studies have evaluated substantially lower weekly doses, including 1, 4, 8, and 12 mg in the Phase 2 obesity program. The phase 2 trial from Jastreboff et al. was dosed at 12mg once weekly, while Phase 3 development has evaluated weekly doses up to 12 mg in the pivotal obesity program reported to date.
| Specification | Details |
| Product Name | Retatrutide 30 mg |
| Research Compound | Retatrutide (LY3437943) |
| Peptide Type | Synthetic triple GIP/GLP-1/glucagon receptor agonist |
| Peptide Length | 39 amino acids |
| Chemical Form | Formulation-dependent; sodium-salt chemical records are available |
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4,731.3 g/mol |
| Quantity | 30 mg |
| Appearance | Formulation-dependent; commonly supplied as a lyophilized research preparation |
| Purity | Research-grade quality |
| Research Status | Research Use Only |
Retatrutide was developed as a single-molecule triple agonist to harness the metabolic benefits of GIP, GLP-1, and glucagon receptors. The study by Sanyal et al. found that retatrutide is a modified peptide hormone, which allows for the activation of multiple receptors and its prolonged circulation in the body. In particular, the authors note that it is a single protein that is linked to a fatty diacid, contributing to its pharmacokinetics, which allow for its once-weekly administration.
The first study evaluated the effects of retatrutide on glucose metabolism and body weight with an emphasis on its safety profile and pharmacokinetics. The following studies then evaluated its effects on obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). According to Rosenstock et al., retatrutide showed dose-dependent reductions in glycemic measures and weight in patients with type 2 diabetes in a randomized controlled trial.
It is hard to say that the mechanism of the drug’s work is based only on one receptor, as it is a triple agonist with activation properties for three different types of receptors. Jastreboff et al., in their work, highlight the discovery of retatrutide as a GIPR agonist. However, Sanyal et al. explain that “the newly developed glucose-dependent insulinotropic polypeptide agonist, retatrutide, has increased potency at human GIPR with reduced activity at human GLP-1R and GCGR compared with endogenous peptide ligands”.
Since it is a GIP analog, GIP receptor activation is part of the triple-agonist activity of retatrutide. It plays an essential role in the mechanism of action of GIP, which affects the process of incretin hormone secretion in the body. Sanyal et al. established the significant potency of retatrutide as compared with endogenous GIP in cellular activity assays of the human GIP receptor.
GLP-1 receptor is the second type of receptor that shows agonistic activity of retatrutide. In general, it is known that GLP-1 plays a key role in regulating glucose levels, food intake, and gastrointestinal motility. Jastreboff et al. conducted an experiment that proved the therapeutic efficiency of retatrutide – the triple agonist of GIP, GLP-1, and glucagon receptors, since the decrease in the participants’ body weight was observed after the treatment with increasing doses of retatrutide.
The activation of glucagon receptors is the key difference between this drug and the previously mentioned incretin agonists. The effect of this hormone can be seen in terms of energy expenditure and substrate utilization, which provides an additional mechanism of action in terms of energy metabolism. Sanyal et al. indicate that retatrutide acts on human GIP, GLP-1, and glucagon receptors and may augment incretin system function and energy expenditure.
Hence, the main rationale behind developing the described pharmaceutical agent is a multifactorial mechanism of action. According to Jastreboff et al., the addition of glucagon receptor agonism to GLP-1 or GIP–GLP-1 therapies could potentially amplify energy expenditure, optimize substrate utilization, and improve other metabolic functions, which requires further investigation.
Nowadays, the reduction of body weight is one of the most prominent effects of the drug candidate retatrutide. In the context of the Phase 2 obesity trial, Jastreboff et al. “reported mean reductions from baseline in body weight of 8.7% with 1 mg, 17.1% with 4 mg combined-dose groups, 22.8% with the 8-mg combined-dose groups, and 24.2% with 12 mg vs. 2.1% with placebo, at week 48”. Moreover, among the treatment-emergent adverse events, the most frequent events were related to gastrointestinal disturbances and were generally mild to moderate
However, the more relevant part of this study refers to the results of the Phase 3 trial that began in 2022. Eli Lilly announced the topline data from TRIUMPH-1, which revealed that patients who received 12 mg of retatrutide lost an average of 28.3% of their body weight after 80 weeks, whereas 45.3% of them reduced their body weight by 30%. Thus, the results of efficacy are promising, although these are investigational Phase 3 data, which do not confirm the 30 mg dose’s safety or effectiveness.
Retatrutide was also studied in patients with type 2 diabetes. Rosenstock et al. performed a randomized Phase 2 trial and found that compared to placebo and active control groups, retatrutide resulted in significant improvements in several glycemic metrics as well as reductions in body weight, thus supporting the exploration of the triple-receptor agonism concept beyond obesity.
The later Phase 3 data further support the drug’s metabolic properties. According to Eli Lilly’s announcement, in the TRANSCEND-T2D-1 trial, participants with type 2 diabetes experienced, on average, a 2.0% decrease in A1C and a 16.8% decrease in body weight, with the longest treatment duration being 40 weeks. This is, of course, preliminary topline data announced by the company ahead of the full results being published in a peer-reviewed journal. This is different from Rosenstock et al. (2023)’s trial, which has already been published in a peer-reviewed journal.
In addition to trials on obesity, the drug was tested on patients with MASLD (metabolic fatty liver disease). As reported by Sanyal et al., in a phase 2a randomized substudy, treatment with retatrutide for 24 weeks was associated with reductions in liver fat content from baseline versus placebo. Specifically, the decreases were observed in all the treatment groups: 42.9%, 57.0%, 81.4%, and 82.4%, for the 1, 4, 8, and 12 mg groups, respectively. In addition, 86% of the 12 mg group had less than 5% of liver fat at week 24.
The findings suggest that future research should be pursued to determine the drug’s impact on liver disease; however, the authors emphasize that their results are limited by a small number of MASLD patients and the lack of liver histology. Therefore, Sanyal et al. conclude that additional trials are required to establish retatrutide’s efficacy in treating liver disease.
The preclinical and clinical research of Retatrutide is extensive, exploring the drug’s receptor pharmacology, conducting early-phase clinical investigations, carrying out randomized controlled trials in phase 2, and embarking on phase 3 trials. In addition to positive results during the research, Retatrutide’s ability to reduce body weight in obese adults has been demonstrated by Jastreboff et al. Rosenstock et al. established the drug’s metabolic and glucose-regulating effects in patients with type 2 diabetes.
The clinical effectiveness of the preparation now expands to a broader range of obesity-associated indications and contraindications. According to Eli Lilly’s announcement, positive top-line results from a Phase 3 trial of Retatrutide in diverse therapeutic areas, including obesity, type 2 diabetes, knee OA pain, and obstructive sleep apnea, were recorded in 2026. Nevertheless, it is essential to keep in mind that Retatrutide is still an investigational drug that has yet to be approved by regulatory agencies.
Current retatrutide research includes:
The breadth of these applications reflects the combined GIP, GLP-1, and glucagon receptor activity of the molecule rather than evidence that every potential application has been clinically established. The study of Sanyal et al. provides evidence of significant reductions in liver fat in the studied population with MASLD, while the work by Jastreboff et al. describes the main findings of the phase II trial, proving efficacy in terms of body-weight reduction.
Retatrutide is an Investigational drug, and as of August 2026, it is not approved by the Food and Drug Administration (FDA) or other health authorities and regulators. According to Reuters, retatrutide was still in phase 3 trials as of August 2026 and had not been approved for use.
Accordingly, a Retatrutide 30 mg research preparation should not be represented as an approved medicine or as a clinically established 30 mg treatment. Clinical findings from lower-dose investigational studies cannot automatically be extrapolated to a 30 mg research preparation.
Storage should follow the validated specification for the particular retatrutide research formulation because peptide stability can vary according to formulation, concentration, excipients, moisture, temperature, and light exposure.
A universal post-reconstitution temperature or storage period should not be assigned without formulation-specific stability data.
It is a research formula that contains a certain amount of 30 mg of the peptide called retatrutide that is classified as an experimental agonist of the GIP, GLP-1, and glucagon receptors.
The peptide has been studied in the context of weight loss and weight control, obesity, type 2 diabetes, metabolic liver disease, and a number of other obesity-related conditions.
No. Published clinical trials have studied substantially lower doses, with 12 mg being the highest dose in the major Phase 2 and currently reported Phase 3 programs. Jastreboff et al. evaluated doses up to 12 mg in the Phase 2 obesity trial.
Retatrutide acts by simultaneously activating GIP, GLP-1, and glucagon receptors, producing an integrated metabolic signal. According to the work of Jastreboff et al. (2023), the drug is a triple hormone-receptor agonist.
If supplied as an RUO research preparation, it is intended solely for laboratory research and should not be represented as a human-use pharmaceutical product.
Retatrutide 30 mg, when supplied as a research substance, is for Research Use Only (RUO). Therefore, it is provided for laboratory research purposes only as an RUO and must not be represented or distributed as an approved pharmaceutical product, an approved clinical dose of 30 mg, or as a product for human consumption.
Storage guidelines
Store at controlled room temperature Keep in original sealed container Do not freeze the vials Maintain stable temperature conditions
Refrigerate immediately at 36°F to 46°F Store at 2°C to 8°C consistently Keep refrigerated between uses Place in clean refrigerator compartment
If left out for more than 4 hours, contact supervisor Do not use if the temperature exposure is exceeded Return to refrigerator promptly after use Monitor storage conditions regularly
Chemical properties
